EG-301
- Generic Name
- EG-301
Dry AMD Therapeutic Pipeline Shows Promise with 70+ Companies Advancing Novel Therapies
• The dry age-related macular degeneration (AMD) therapeutic landscape is robust, with over 70 companies developing more than 80 therapies.
• Key companies like Alkeus Pharmaceuticals and Roche are evaluating new drugs, aiming to improve the treatment options for dry AMD.
• Recent clinical trials show promise, with Ocugen reporting positive data for OCU410 and Eyestem Research achieving a milestone in cell therapy for geographic atrophy.
• Several therapies, including gene therapies and complement inhibitors, are in various clinical trial phases, addressing the unmet needs in dry AMD treatment.
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.
© Copyright 2025. All Rights Reserved by MedPath